Related Experiment Video
Updated: Jul 22, 2026
A Cell Free Assay System Estimating the Neutralizing Capacity of GM-CSF Antibody using Recombinant Soluble GM-CSF Receptor
Published on: June 27, 2011
A meta-analysis of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody treatment for COVID-19 patients
Jin-Tao Guan1, Wei-Jie Wang2, Du Jin1
1The First People's Hospital of Taizhou, Zhejiang, China.
Insights
Granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies show promise in treating COVID-19 patients. This analysis found a reduced risk of death but an increased need for ventilation in patients receiving GM-CSF antibody treatment.
Area of Science:
- Immunology
- Virology
- Critical Care Medicine
Background:
- COVID-19 poses a significant global health threat, necessitating research into effective treatments.
- Granulocyte-macrophage colony-stimulating factor (GM-CSF) plays a role in immune responses and inflammation, making it a potential therapeutic target in viral infections.
Purpose of the Study:
- To evaluate the efficacy and safety of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in managing COVID-19.
- To assess the impact of GM-CSF antibody treatment on mortality, ICU admission, ventilation requirements, and secondary infections in COVID-19 patients.
Main Methods:
- A systematic literature search was conducted across major databases (PubMed, Cochrane Library, Embase, Google Scholar, Baidu Scholar) from December 2019 to January 2021.
- A meta-analysis using a random-effect model was performed on 12 eligible studies involving 8979 COVID-19 patients.
Main Results:
- GM-CSF antibody treatment was associated with a significant 23% reduction in the risk of death (OR: 0.34, 95% CI: 0.21-0.56).
- Treatment with GM-CSF antibodies led to a 20% increase in the requirement for ventilation (OR: 1.47, 95% CI: 1.19-1.80).
- No significant correlation was found between GM-CSF antibody treatment and secondary infections or ICU admission risk.
Conclusions:
- GM-CSF antibodies may offer clinical benefits for severe COVID-19 patients.
- The findings suggest a complex role for GM-CSF modulation in COVID-19, with potential benefits in reducing mortality but also risks of increased ventilation needs.
Objective:
This meta-analysis aims to assess the efficacy and safety of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies on COVID-19.
Methods:
Relevant literatures about GM-CSF antibody treatment in COVID-19 patients were searched from the PubMed, Cochrane Library, Embase, Google scholar, and Baiduscholar databases from the COVID-19 outbreak in December 2019 until 1 January 2021. The primary outcomes included the death, intensive care unit (ICU) admission risk, ventilation requirement, and secondary infection.
Results:
A total of 12 eligible literature involving 8979 COVID-19 patients were recruited, and they were divided into experimental group (n = 2673) and control group (n = 6306). Using a random-effect model, it is found that the GM-CSF antibody treatment was associated with a 23% decline of the risk of death [odd's ratio (OR): 0.34, 95% confidence interval (CI): 0.21-0.56, p < 0.0001] and a 20% enhancement of ventilation (OR: 1.47, 95% CI: 1.19, 1.80, p = 0.0002). GM-CSF antibody treatment did not have a significant correlation to secondary infection and increased risk of ICU admission in COVID-19 patients, which may be attributed to the older age and the length of stay.
Conclusions:
Severe COVID-19 patients can benefit from GM-CSF antibodies.
Related Concept Videos
01:15Differentiation of Common Myeloid Progenitor Cells
01:01Regulation of Hematopoietic Stem Cells